Mandate

Vinge advised Statoil in connection with its acquisition of minority shareholding in Lundin Petroleum

Vinge advised Statoil in connection with its acquisition of shares in Lundin Petroleum AB (publ) corresponding to approximately 12 percent of the shares and votes. The total purchase price amounted to approximately SEK 4.6 billion.
 
Statoil is an international energy company with approximately 22,000 employees and operations in 36 countries. Statoil is headquartered in Stavanger, Norway, and is listed on the New York Stock Exchange and Oslo Børs.
 
Vinge’s team consisted of Göran Nyström, Dain Hård Nevonen and Rikard Lindahl.

Related

Vinge advises Fortinova Fastigheter AB (publ) on its first SEK 200 million green bond issue

Vinge has advised Fortinova Fastigheter AB (publ) (“Fortinova”) on the company’s first issue of senior unsecured green bonds in an aggregate principal amount of SEK 200 million, under a framework of up to SEK 600 million. Nordea, acted as sole bookrunner in connection with the bond issue.
September 18, 2026

Vinge advises Morrow Bank AB (publ) in connection with the bank’s sale of parts of MedMera Bank and the sale of NPL portfolios

Vinge has advised Morrow Bank AB (publ) in connection with the divestment of parts of MedMera Bank’s operations to a leading global credit investment firm. The divestment is structured as a sale of shares and priced at a premium of approximately SEK 90 million above equity value as per the completion date. The transaction includes parts of MedMera’s banking operations such as IT infrastructure, organisation and management, whilst Morrow Bank retains MedMera’s performing loans, deposits, customers, the MedMera brand, the Coop partnership agreement as well as key personnel.
September 15, 2026

Vinge advises HealthCap in conjunction with its investment in AMRA Medical

HealthCap is investing in AMRA Medical AB, a company that analyses whole-body MRI images to classify and quantify an individual’s muscle and fat tissue throughout the body and places this in relation to human health and disease.
September 15, 2026